You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 17, 2024

HYLENEX RECOMBINANT Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Recent Clinical Trials for HYLENEX RECOMBINANT

Identify potential brand extensions & biosimilar entrants

SponsorPhase
United States Department of DefensePhase 1
AstraZenecaPhase 1
The Wistar InstitutePhase 1

See all HYLENEX RECOMBINANT clinical trials

Recent Litigation for HYLENEX RECOMBINANT

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Halozyme, Inc. v. Lee2016-12-19
Halozyme, Inc. v. Lee2016-12-18

See all HYLENEX RECOMBINANT litigation

Pharmacology for HYLENEX RECOMBINANT
Established Pharmacologic ClassEndoglycosidase
Chemical StructureGlycoside Hydrolases
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for HYLENEX RECOMBINANT Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for HYLENEX RECOMBINANT Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Halozyme Therapeutics, Inc. HYLENEX RECOMBINANT hyaluronidase human Injection 021859 ⤷  Try a Trial 2039-09-22 Company disclosures
Halozyme Therapeutics, Inc. HYLENEX RECOMBINANT hyaluronidase human Injection 021859 ⤷  Try a Trial 2023-03-05 Company disclosures
Halozyme Therapeutics, Inc. HYLENEX RECOMBINANT hyaluronidase human Injection 021859 ⤷  Try a Trial 2023-03-05 Company disclosures
Halozyme Therapeutics, Inc. HYLENEX RECOMBINANT hyaluronidase human Injection 021859 ⤷  Try a Trial 2023-03-05 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for HYLENEX RECOMBINANT Derived from Patent Text Search

These patents were obtained by searching patent claims

Supplementary Protection Certificates for HYLENEX RECOMBINANT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
PA2016022 Lithuania ⤷  Try a Trial PRODUCT NAME: RITUKSIMABAS; REGISTRATION NO/DATE: EU/1/98/067/001-002 20140321
CR 2016 00031 Denmark ⤷  Try a Trial PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; NAT. REG. NO/DATE: EU/1/98/067/003-004 20140326; FIRST REG. NO/DATE: EU EU/1/98/067 20140326
300753 Netherlands ⤷  Try a Trial PRODUCT NAME: TRASTUZUMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
CA 2016 00031 Denmark ⤷  Try a Trial PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326
C02405015/01 Switzerland ⤷  Try a Trial PRODUCT NAME: RITUXIMAB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65813 28.06.2016
CA 2015 00043 Denmark ⤷  Try a Trial PRODUCT NAME: TRASTUZUMAB OG REKOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: C(20135603) /EU/1/00/145/002 20130826
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.